Tesamorelin: A Growth-Hormone Research Overview
All information here is for laboratory and educational research only. No compound referenced is approved for human or veterinary use, and nothing here is medical advice.
- Tesamorelin is a peptide that prompts the body's natural growth-hormone release, and it has real human trial data.
- It is FDA-approved (as Egrifta) for one narrow use: reducing excess belly fat in people with HIV-associated lipodystrophy.
- Outside that approved use it is discussed in fitness communities, but those are unverified anecdotes.
- BioRegen does not sell it for human use.
- BioRegen supplies tesamorelin reference material strictly for laboratory and educational research.
All information here is for laboratory and educational research only. No compound referenced is approved for human or veterinary use, and nothing here is medical advice. Tesamorelin is a lab-made copy of a natural body signal called growth-hormone-releasing hormone, or GHRH. Scientists have studied it in published research to see how it affects the system that controls growth hormone. This page sums up, in plain terms, what researchers have looked at, so lab professionals have a quick reference. Everything here is reported from the research, not claimed by us.
What Tesamorelin Is
The research describes tesamorelin as a steady, lab-made version of a natural body signal called GHRH(1-44). In the body, GHRH is made in the brain and tells a small gland, the pituitary, to release growth hormone. Tesamorelin is a copy of that signal, with one small change to its structure. Researchers added that change to help it last longer before the body breaks it down. In published work, scientists group it with other GHRH copies, such as sermorelin and CJC-1295. In the lab, it is studied as a reference peptide and as a way to learn how the GHRH signal works.
Mechanism and What Research Explores
Studies describe tesamorelin as something that switches on the GHRH receptor. Think of the receptor as a lock on the pituitary gland, and tesamorelin as a key that fits it. When the key turns the lock, the gland sends out the body's own growth hormone in natural bursts. That growth hormone is then linked to changes in another signal called insulin-like growth factor 1, or IGF-1. In published trials with people who carried extra deep belly fat, researchers measured a rise in IGF-1 in the blood and used CT scans to look at changes in that deep belly fat. Because this approach nudges the body to make its own growth hormone, instead of adding growth hormone from outside, scientists often focus on how those natural bursts are triggered.
Research Stage and Limitations
Tesamorelin has been tested in careful clinical studies. These ran at several sites at once, and neither the patients nor the staff knew who got the real compound and who got a dummy, which helps keep the results honest. Most of that published data comes from specific groups of study patients, not the general public. Researchers stress that the results depend on the setting. What shows up in one group under tight lab conditions may not carry over to other people, and the studies differ in what they measured, how long they ran, and what counted as a result. Other papers focus on building lab methods to detect GHRH copies, which shows there is interest in how the body handles them and how little is known about copies that are not approved. Any talk about tesamorelin in online groups or forums should be treated as unverified personal stories, not proven findings. BioRegen does not make or back any claims based on them. Researchers should trust peer-reviewed studies over informal accounts.
Laboratory Handling Notes
Tesamorelin is a peptide, so labs usually keep it as a dry, freeze-dried powder. It is easily harmed by heat, moisture, and by being frozen and thawed over and over. Lab guides in the research describe mixing the powder back into liquid with a suitable sterile fluid in the lab, handling it gently so it does not break down, and keeping both the powder and the mixed liquid cold. For general background on getting research peptides ready, see our overview on how to reconstitute peptides. These notes just describe lab practice. They are not directions for any use in people or animals.
Is tesamorelin the same as growth hormone?
No. Research describes tesamorelin as a GHRH copy that works one step earlier, by prompting the pituitary gland. Growth hormone is the hormone that comes out after that. So they sit at different points in the chain, and studies treat them as two separate things.
How does tesamorelin compare to other GHRH analogs?
Published lab work groups tesamorelin with other GHRH copies like sermorelin and CJC-1295, and points out how they differ in structure and in how the body breaks them down. The studies that compare them look at how stable each one is and how it works on the receptor, not at any use.
Where can I learn about related research compounds?
Our research finder helps you find background on peptides studied in the lab, and the growth research category lists reference materials in this area.
Selected Research References
- Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two phase 3 trials. J Clin Endocrinol Metab. 2010. https://doi.org/10.1210/jc.2010-0490
- Memdouh S, et al. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Test Anal. 2021. https://doi.org/10.1002/dta.3183
Reference metadata sourced via PubMed.
Expanding your laboratory reference library? Explore our research guide for background on working with research peptides, and create a free account for 10% off your first order. You can also browse reference materials in the growth research category. For a broader comparison of incretin research peptides, see our overview of retatrutide vs tirzepatide vs semaglutide.
All information on this page is provided strictly for laboratory and educational research purposes. No compound referenced is approved for human or veterinary use, and nothing here constitutes medical advice. BioRegen does not make or endorse any therapeutic claims. Products are not intended to diagnose, treat, cure, or prevent any disease.